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Craniectomy for Traumatic Intracranial Hypertension
To the Editor: In the Randomised Evaluation of 
Surgery with Craniectomy for Uncontrollable Ele-
vation of Intracranial Pressure (RESCUEicp) trial 
reported by Hutchinson and others (Sept. 22 is-
sue),1 mortality among patients with severe trau-
matic brain injury (TBI) and refractory intracra-
nial hypertension who underwent decompressive 
craniectomy was lower than that among patients 
who received medical care. However, at 6 months, 
patients in the surgical group were more likely to 
have severe disability (as assessed with the use of 
the Extended Glasgow Outcome Scale [GOS-E]2) 
than patients in the medical group. At 12 months, 
a higher percentage of patients in the surgical 
group than in the medical group had a favorable 
outcome.
Although most patients in the surgical group 
underwent a bifrontal decompressive craniectomy 
(63%), an analysis according to the type of sur-
gery (i.e., bifrontal or unilateral craniectomy) was 
not performed. This analysis would be helpful 
given that in the United States, unilateral de-
compressive craniectomy is a more common sur-
gical decompression procedure than bifrontal 
decompressive craniectomy.
This trial included children as young as 10 
years of age. Since among patients with severe 
TBI, school-aged children generally tend to have 
better outcomes than adults,3,4 these patients per-
haps should be assessed with a pediatric version 
of the GOS-E in a separate subgroup analysis.5
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To the Editor: The RESCUEicp trial showed 
that among patients with traumatic intracranial 
hypertension, decompressive craniectomy, as com-
pared with medical therapy, reduced mortality 
and increased rates of vegetative state, lower se-
vere disability, and upper severe disability. Can 
the authors indicate whether patients in the sur-
gical group had already undergone cranioplasty 
(replacement of the bone flap over the defect) when 
functional outcome was assessed at 6 months? 
Cranioplasty improves cerebral perfusion and re-
verses abnormal physiological features of cerebro-
spinal fluid caused by decompressive craniectomy,1,2 
this week’s letters
2401 Craniectomy for Traumatic Intracranial 
Hypertension
2404 Dietary Sodium and Cardiovascular Disease Risk
2408 Multiple Variants of Klebsiella pneumoniae Producing 
Carbapenemase in One Patient
 e50 Betrixaban in Acutely Ill Medical Patients
The New England Journal of Medicine 
Downloaded from nejm.org at CAMBRIDGE UNIVERSITY LIBRARY on August 5, 2019. For personal use only. No other uses without permission. 
 Copyright © 2016 Massachusetts Medical Society. All rights reserved. 
T h e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
n engl j med 375;24 nejm.org December 15, 20162402
and in clinical practice it is often associated with 
improvement in neurologic status.3
If patients in the surgical group did not un-
dergo cranioplasty before the outcome assess-
ment at 6 months, the benefit of decompressive 
craniectomy may have been underestimated. 
Would the authors consider reporting the rate of 
cranioplasty at 6 months among patients in the 
surgical group? Also, would they consider per-
forming a post hoc subgroup analysis to shed 
light on whether cranioplasty changes the effect 
of initial decompressive surgery on functional 
outcome at 6 months?
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To the Editor: In the RESCUEicp trial, the di-
chotomization of “favorable outcomes” in the pa-
tients depends on the definition of a “favorable” 
outcome. The conventional definition in patients 
with TBI is full independence at 6 months (moder-
ate disability or better).1 In the RESCUEicp trial, 
the proportion of patients with these favorable 
outcomes was just 26.6% in the medical group 
and 27.4% in the surgical group, as compared 
with the reported “favorable outcomes” (34.6% in 
the medical group and 42.8% in the surgical 
group; P = 0.12). Figure 2 of the article may not 
precisely reflect this result. In the surgical group, 
all “22 more survivors” described were in a vegeta-
tive state or were severely disabled. None were 
independent (a favorable outcome according to 
the conventional definition).
Furthermore, the increased rate of survival 
at 6 months may relate to high mortality 
among patients in the medical group (48.9%), 
as compared with 18% mortality among pa-
tients in the medical group of the Decompres-
sive Craniectomy (DECRA)2 trial. In both the 
DECRA and RESCUEicp trials, decompressive 
craniectomy was a last-tier intervention, and the 
proportion of patients with conventional favorable 
outcomes after craniectomy in the DECRA trial 
(30%) was similar to that in the RESCUEicp trial. 
In both trials, decompressive craniectomy in-
creased disability and did not increase full inde-
pendence in survivors.
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To the Editor: The RESCUEicp trial showed a 
significant superiority of decompressive craniec-
tomy over medical management in preventing 
death among patients with TBI and refractory 
intracranial hypertension. These results appear 
to be contrary to the results of the DECRA trial. 
In addition, mortality among patients in the 
medical group of the RESCUEicp trial was 48.9%, 
as compared with 18% among patients in the 
medical group in the DECRA trial.
Another point that merits mention is that 
37.2% of the patients in the medical group in the 
RESCUEicp trial underwent decompressive crani-
ectomy because of clinical deterioration. There-
fore, it is reasonable to speculate that the medi-
cal therapy received after randomization may 
not have been adequate in the medical group. 
Although treatment with barbiturates is often 
regarded as a final-tier treatment, their efficacy 
in controlling refractory elevation of intracranial 
pressure is controversial.1 It may be necessary 
to increase the intensity of medical treatment to 
manage uncontrolled intracranial pressure. Fur-
ther explanation of this aspect of the trial would 
be appreciated.
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To the Editor: In the RESCUEicp trial involving 
patients with refractory traumatic intracranial 
hypertension, decompressive craniectomy result-
ed in lower mortality than mortality among pa-
tients who received medical care. However, sur-
vivors tended to cluster in the GOS-E category of 
upper severe disability. Whether this degree of 
disability is acceptable will depend on the pa-
tient, his or her family, and societal influences.
This trial further showed that decreasing intra-
cranial pressure does not treat primary brain in-
jury. Mediation of the secondary injuries (hernia-
tion and ischemia) resulting from traumatic 
intracranial hypertension does not directly ad-
dress the variable underlying pathophysiological 
processes. Thus, the degree of injury in the 
“rescued” patients in the RESCUEicp trial mani-
fested itself as severe disability.
The RESCUEicp trial joins a large and grow-
ing body of “failed” randomized, controlled trials 
involving treatment of patients with TBI and in-
tracranial pressure,1-4 and the best consequence 
of this trial would be to end the era of focusing 
on intracranial pressure alone and of applying 
one management algorithm to all manifestations 
of intracranial hypertension. Until clinicians and 
clinical researchers begin to target the various 
pathophysiological processes underlying elevated 
intracranial pressure, the list of large, negative 
trials is likely to continue to grow.
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The authors reply: In reply to Huh et al. and 
Gaberel and colleagues: exploratory analyses to 
evaluate craniectomy sites and pediatric outcomes, 
both of which are important issues, are ongoing. 
Also, the timing of cranioplasty may affect out-
comes after TBI. The initiation of a prospective 
registry for cranioplasties in the United Kingdom 
is under way.1
With regard to the comments by Cooper et al. 
and Hu and Wang, the contrasting results of the 
DECRA and RESCUEicp trials are due to differ-
ent hypotheses, inclusion criteria, and therapeutic 
protocols. The DECRA trial, as compared with 
the RESCUEicp trial, enrolled patients with a lower 
intracranial-pressure threshold (20 mm Hg vs. 
25 mm Hg) for shorter intervals (15 minutes vs. 
1 to 12 hours), after lower intensities of therapy 
(stage 1 interventions vs. stage 1 and 2 interven-
tions), and within a shorter interval after injury 
(all patients enrolled within 72 hours after in-
jury vs. 44% of patients enrolled >72 hours after 
injury). Patients with intracranial hematomas 
were enrolled in the RESCUEicp trial, but they 
were not enrolled in the DECRA trial. At enroll-
ment, the populations also differed with respect 
to expected outcome; the requirement for stage 2 
interventions increases the relative risk of death 
by 60%.2 Hence, at 6 months, the pooled mortal-
ity of 37.5% in the RESCUEicp trial versus 18.7% 
in the DECRA trial is unsurprising.
In addition, our primary analysis showed a 
significant between-group difference in the GOS-E 
distribution and a substantial reduction in mor-
tality with surgery; this finding differed from 
that of the DECRA trial, in which mortality was 
similar in the two groups. The severity of injury 
in the RESCUEicp trial underpinned dichotomi-
zation in the prespecified sensitivity analysis at 
upper severe disability (independent at home) or 
better. Given the high expectation of a poor out-
come, the use of a “conventional” dichotomy 
would be as inappropriate as the use of it in 
populations with mild TBI (in whom disability-
free survival is often attainable). This approach is 
concordant with recent recommendations.3 Up-
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per severe disability is a better outcome than a 
modified Rankin score of 4 (on a scale from 0 
[no symptoms] to 6 [death]), the threshold that 
has driven the use of craniectomy in patients with 
ischemic stroke (Table 1).4
Also, barbiturates were an option in patients 
in the medical group after randomization. The 
fact that 37.2% of patients in the medical group 
eventually underwent a craniectomy, whereas 
9.4% of patients in the surgical group required 
barbiturates, indicates that the failure to control 
intracranial pressure was greater in the medical 
group.
We agree with Chesnut about the acceptability 
of disability but question the statement regarding 
“failed” trials. The DECRA trial and the European 
Study of Therapeutic Hypothermia (32°C–35°C) for 
Intracranial Pressure Reduction after Traumatic 
Brain Injury (the Eurotherm3235 Trial) were 
valuable because they showed that craniectomy 
and hypothermia, respectively, are not beneficial 
as stage 2 interventions. The progesterone trial 
by Wright et al., which was cited by Chesnut as 
a failed trial, did not address intracranial hyper-
tension. We think that the treatment of intracra-
nial hypertension will remain important, since it 
is a driver of increased mortality.5 Integration of 
intracranial-pressure waveform analysis (in order 
to characterize autoregulation) with multimodal-
ity monitoring (microdialysis, brain oxygenation, 
and electrocorticography) can identify patho-
physiological subgroups and may allow targeted 
treatment after TBI.
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Dietary Sodium and Cardiovascular Disease Risk
To the Editor: Cogswell et al. (Aug. 11 issue)1 
argue that the reported association between low 
sodium intake and increased cardiovascular risk 
does not fulfill the criteria for causality, and they 
therefore conclude that low sodium intake should 
be recommended. We wish to call attention to 
several issues in their assessment of the avail-
able data.
First, the criticism by Cogswell et al. with 
regard to fasting urinary sodium estimates of 
Scale and Category Definition
Extended Glasgow Outcome Scale
Upper severe disability Patient does not require assistance at home (or can be left alone 
for at least 8 hr) but requires assistance outside the home
Lower severe disability Patient is dependent on others for care
Modified Rankin scale*
Moderately severe disability (a score of 4) Patient is unable to walk without assistance and unable to attend 
to his or her own bodily needs without assistance
Severe disability (a score of 5) Patient is bedridden, incontinent, and requires constant nursing 
care and attention
*  Scores on the modified Rankin scale, which assesses the degree of disability or dependence in daily activities, range 
from 0 (no symptoms) to 6 (death).
Table 1. Definitions of Severe Disability According to the Extended Glasgow Outcome Scale and the Modified Rankin Scale.
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